Every biotech breakthrough, no matter which company makes it or which drug wins, runs on the same underlying equipment: the instruments, reagents, and consumables that fill every lab. The companies that sell these tools are the picks-and-shovels of the industry, and they occupy an enviable position, because they profit from the whole field’s activity without betting on any single drug. Here are the notable players, grouped by what they provide, and why this quiet corner of biotech is so strategically important.
Why the tools layer matters
Drug developers live or die by their pipelines; a single trial failure can sink a company. Tools companies face a very different risk profile. They supply the entire industry, so their fortunes track the overall level of research and manufacturing activity rather than the success of any one program. When the whole sector is busy, discovering, testing, and making drugs, the tools companies prosper regardless of whose molecule wins. That durability is why investors often treat this layer as a more stable way to gain exposure to biotech’s growth, and why the companies here are among the largest and most consistently profitable in all of life science.
The diversified giants
A handful of enormous companies span instruments, reagents, and consumables across nearly every corner of the lab.
- Thermo Fisher Scientific is the dominant force in the field, an unrivaled breadth of instruments, reagents, consumables, and services that touches almost every laboratory on earth.
- Danaher is a life-science powerhouse whose family of businesses, including Beckman Coulter, SCIEX, Leica, Molecular Devices, Cytiva, and Aldevron, spans diagnostics, bioprocessing, and research tools.
- Merck KGaA (operating as MilliporeSigma in the life-science market) supplies a vast catalog of reagents, chemicals, and lab materials.
- Agilent Technologies is a leader in analytical instruments such as chromatography and mass spectrometry, and Bio-Rad Laboratories and Revvity round out the group of broad, established suppliers.
The analytical instrument specialists
Some companies are defined by excellence in specific, high-value instrument categories. Waters Corporation and Bruker are leaders in chromatography, mass spectrometry, and related analytical technologies that labs rely on to identify and measure molecules with precision. These instruments are the workhorses behind everything from drug characterization to quality control, and the companies that make them hold deep, sticky positions in the market.
Sequencing and genomics tools
The genomics revolution runs on specialized hardware. Illumina is the long-dominant provider of DNA sequencing instruments, the machines that made modern genomics affordable, and it now faces a lively field of challengers pushing on cost, speed, and read length. 10x Genomics leads in single-cell and spatial biology tools that let researchers examine biology at extraordinary resolution, and long-read and emerging sequencing companies are expanding what is possible. As genomics moves deeper into medicine, this category keeps growing in importance.
Bioprocessing: the tools for making biologics
As biologics and advanced therapies have boomed, so has demand for the specialized equipment used to manufacture them, bioreactors, filtration, purification, and the single-use systems that modern biomanufacturing relies on. Sartorius and Cytiva are leaders in this bioprocessing space, and Repligen specializes in the technologies that improve biologics production. This category is tied directly to the growth of biologics and cell and gene therapy manufacturing, which makes it one of the more dynamic parts of the tools landscape.
Lab automation and the rest
Rounding out the field are the companies that automate the lab, providing robotic liquid handlers and automated systems that let labs run more experiments with fewer hands, alongside specialists in sample preparation, molecular biology reagents, and laboratory distribution that keep research supplied. Together with the giants and specialists above, they form the dense supply chain that every experiment, in every biotech, quietly depends on.
What to look for in this space
If you are evaluating tools companies, as an investor, a partner, or a buyer, the relevant questions are about durability and position. How essential and sticky is the product, does switching away carry real cost and risk, which protects the supplier? How much of the revenue is recurring, from consumables and reagents that customers must keep buying, rather than one-time instrument sales? And how exposed is the company to the overall health of biotech research and manufacturing spending, which rises and falls with funding cycles? The strongest tools companies combine essential products, high recurring revenue, and broad exposure to the whole industry’s growth.
The bigger picture
The tools layer rarely makes headlines, but it is foundational: no drug gets discovered, tested, or manufactured without it. For anyone trying to understand biotech, or invest in it, the picks-and-shovels companies offer a clear-eyed view of the industry’s overall activity and a more stable form of exposure to its long-term growth. This snapshot captures the notable players, but the sector consolidates and evolves continually.
Funding cycles and the consolidation machine
Two dynamics are worth understanding about how this sector behaves. The first is its sensitivity to research and manufacturing spending. Although tools companies are more stable than drug developers, they are not immune to the biotech funding cycle: when capital is scarce and biotechs cut spending, orders for instruments, reagents, and consumables soften, and when funding flows and the industry expands, demand accelerates. The good news for these companies is that a large share of their revenue is recurring, the reagents and consumables customers must keep buying to run experiments, which cushions the swings and makes their businesses far more predictable than a pipeline-dependent biotech. Still, the sector’s health is a useful barometer of the industry’s overall activity, and its results often signal broader trends in research spending before they show up elsewhere.
The second dynamic is relentless consolidation. The largest tools companies are, to a significant degree, acquisition machines, built and continually reshaped by buying specialists and folding them into ever-broader portfolios. This is why a single giant can span diagnostics, bioprocessing, sequencing, and research reagents: it assembled those capabilities through a long series of deals. For customers, this consolidation brings the convenience of one-stop suppliers but also concentrates the market in a few very large hands. For investors, the steady M&A is part of the appeal, since the biggest players compound growth by acquiring the innovation happening at smaller companies. Either way, the roster of who owns whom shifts continually, so it is worth checking the current corporate landscape rather than relying on a static picture when you evaluate the space.
Why investors pay attention to this quiet sector
The life-science tools sector rarely generates dramatic headlines, which is precisely part of its appeal to investors. Because these companies supply the entire industry rather than betting on individual drugs, they offer exposure to biotech’s long-term growth without the binary risk of a clinical trial that either succeeds or fails. Their large recurring revenue from consumables and reagents makes their businesses unusually predictable, and their essential, hard-to-switch products give them durable pricing power. The tradeoff is that they are tied to overall research and manufacturing spending, so they rise and fall with the industry’s funding cycles, but even then they tend to be far steadier than the drug developers they serve. Add in the sector’s history of steady consolidation, with the largest players compounding growth by acquiring innovative specialists, and you have a category that many see as one of the most reliable ways to invest in the secular growth of life science. Whether you are an investor, a supplier, or simply trying to understand the industry, the tools companies offer a clear window into how much real activity is happening across biotech, because when the whole field is discovering, testing, and making medicines, it is these companies that quietly supply the means.
For the full, regularly updated map of lab equipment and life-science tools companies, browse the BioMed Nexus lab equipment and life-science tools directory, and to follow the launches, acquisitions, and capacity investments across the space, the daily brief covers it as it happens.
Frequently asked questions
What are the biggest life-science tools companies?
The largest diversified suppliers are Thermo Fisher Scientific and Danaher, followed by Merck KGaA (MilliporeSigma), Agilent Technologies, Bio-Rad and Revvity. Specialists include Waters and Bruker in analytical instruments, Illumina and 10x Genomics in sequencing and genomics, and Sartorius, Cytiva and Repligen in bioprocessing.
Why are life-science tools companies considered a stable investment?
Tools companies supply the entire industry rather than betting on a single drug, so their fortunes track overall research and manufacturing activity instead of any one program's success. Many also earn substantial recurring revenue from consumables and reagents, making them a more durable way to gain exposure to biotech's growth.
What is bioprocessing equipment?
Bioprocessing equipment is the specialized machinery used to manufacture biologics and advanced therapies, including bioreactors, filtration and purification systems, and single-use technologies. Demand has grown alongside the boom in biologics and cell and gene therapy manufacturing, with Sartorius, Cytiva and Repligen among the leaders.
